Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1542

1.

Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women.

Xu Y, Ma X, Pan X, He X, Xiao Y, Bao Y.

Cardiovasc Diabetol. 2018 Nov 13;17(1):143. doi: 10.1186/s12933-018-0786-9.

2.

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity.

Luo M, Zhang Z, Peng Y, Wang S, Peng D.

Cardiovasc Diabetol. 2018 Nov 8;17(1):142. doi: 10.1186/s12933-018-0785-x.

3.

Platelet activity and hypercoagulation in type 2 diabetes.

Pretorius L, Thomson GJA, Adams RCM, Nell TA, Laubscher WA, Pretorius E.

Cardiovasc Diabetol. 2018 Nov 2;17(1):141. doi: 10.1186/s12933-018-0783-z.

4.

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.

Besch G, Perrotti A, Salomon du Mont L, Puyraveau M, Ben-Said X, Baltres M, Barrucand B, Flicoteaux G, Vettoretti L, Samain E, Chocron S, Pili-Floury S.

Cardiovasc Diabetol. 2018 Nov 1;17(1):140. doi: 10.1186/s12933-018-0784-y.

5.

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study.

Liu X, Yang ZG, Gao Y, Xie LJ, Jiang L, Hu BY, Diao KY, Shi K, Xu HY, Shen MT, Ren Y, Guo YK.

Cardiovasc Diabetol. 2018 Oct 30;17(1):139. doi: 10.1186/s12933-018-0782-0.

6.

Lower extremity arterial disease in patients with diabetes: a contemporary narrative review.

Nativel M, Potier L, Alexandre L, Baillet-Blanco L, Ducasse E, Velho G, Marre M, Roussel R, Rigalleau V, Mohammedi K.

Cardiovasc Diabetol. 2018 Oct 23;17(1):138. doi: 10.1186/s12933-018-0781-1. Review.

7.
8.

Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction.

Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CI, Goldberg RJ.

Cardiovasc Diabetol. 2018 Oct 19;17(1):136. doi: 10.1186/s12933-018-0779-8.

9.

Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical aortic valve replacement in Spain (2001-2015).

López-de-Andrés A, Perez-Farinos N, de Miguel-Díez J, Hernández-Barrera V, Méndez-Bailón M, de Miguel-Yanes JM, Jiménez-García R.

Cardiovasc Diabetol. 2018 Oct 16;17(1):135. doi: 10.1186/s12933-018-0780-2.

10.

Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword.

Qi XY, Qu SL, Xiong WH, Rom O, Chang L, Jiang ZS.

Cardiovasc Diabetol. 2018 Oct 10;17(1):134. doi: 10.1186/s12933-018-0777-x. Review.

11.

Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.

Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R.

Cardiovasc Diabetol. 2018 Oct 9;17(1):133. doi: 10.1186/s12933-018-0776-y.

12.

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.

Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.

Cardiovasc Diabetol. 2018 Oct 8;17(1):132. doi: 10.1186/s12933-018-0775-z.

13.

Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.

Lee S, Ay C, Kopp CW, Panzer S, Gremmel T.

Cardiovasc Diabetol. 2018 Sep 29;17(1):131. doi: 10.1186/s12933-018-0774-0.

14.

Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus.

Chao CT, Wang J, Chien KL; COhort of GEriatric Nephrology in NTUH (COGENT) study group.

Cardiovasc Diabetol. 2018 Sep 27;17(1):130. doi: 10.1186/s12933-018-0772-2.

15.

Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis.

Ida S, Kaneko R, Murata K.

Cardiovasc Diabetol. 2018 Sep 27;17(1):129. doi: 10.1186/s12933-018-0773-1.

16.

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.

Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder RE.

Cardiovasc Diabetol. 2018 Sep 19;17(1):128. doi: 10.1186/s12933-018-0770-4.

17.

ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus.

Liu C, Li Y, Guan T, Lai Y, Shen Y, Zeyaweiding A, Zhao H, Li F, Maimaiti T.

Cardiovasc Diabetol. 2018 Sep 18;17(1):127. doi: 10.1186/s12933-018-0771-3.

18.

The role of physical activity in the development of first cardiovascular disease event: a tree-structured survival analysis of the Danish ADDITION-PRO cohort.

Amadid H, Johansen NB, Bjerregaard AL, Brage S, Færch K, Lauritzen T, Witte DR, Sandbæk A, Jørgensen ME, Vistisen D.

Cardiovasc Diabetol. 2018 Sep 12;17(1):126. doi: 10.1186/s12933-018-0769-x.

19.

Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy.

Timpka S, Markovitz A, Schyman T, Mogren I, Fraser A, Franks PW, Rich-Edwards JW.

Cardiovasc Diabetol. 2018 Sep 10;17(1):124. doi: 10.1186/s12933-018-0764-2.

20.

Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias.

Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Bollow A, Taton G, Reichelt T, Ellguth D, Engelke N, Hoppner J, El-Battrawy I, Mashayekhi K, Weiß C, Borggrefe M, Akin I.

Cardiovasc Diabetol. 2018 Sep 10;17(1):125. doi: 10.1186/s12933-018-0768-y.

Supplemental Content

Loading ...
Support Center